中国癌症杂志 ›› 2017, Vol. 27 ›› Issue (11): 890-895.doi: 10.19401/j.cnki.1007-3639.2017.11.009

• 论著 • 上一篇    下一篇

表柔比星联合奥沙利铂及氟尿嘧啶的化疗方案提高局部进展期胃癌根治性手术机会的研究

刘晓文,龙子雯,蔡 宏,王亚农   

  1. 复旦大学附属肿瘤医院胃外科,复旦大学上海医学院肿瘤学系,上海 200032
  • 出版日期:2017-11-30 发布日期:2017-12-12
  • 通信作者: 王亚农 E-mail:wangyn1111@hotmail.com

Preoperative chemotherapy using the modified EOF regimen in patients with locally advanced gastric cancer: to increase the chance of radical surgery

LIU Xiaowen, LONG Ziwen, CAI Hong, WANG Yanong   

  1. Department of Gastric Surgery, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China
  • Published:2017-11-30 Online:2017-12-12
  • Contact: WANG Yanong E-mail: wangyn1111@hotmail.com

摘要: 背景与目的:转化性化疗能使肿瘤降期,提高胃癌根治性手术的切除率,改善胃癌患者的预后。本研究旨在探讨EOF方案是否可以提高局部晚期胃癌根治性手术切除率,同时评价转化性化疗的安全性和耐受性。方法:30例经病理证实为胃癌的患者,影像学评估为潜在可根治的局部进展期胃癌入组。采用EOF方案进行治疗,具体为奥沙利铂130 mg/m2,静脉注射(2 h),第1天;表柔比星50 mg/m2,静脉注射(2 h),第1天;氟尿嘧啶2 400 mg/m2,静脉注射(48 h),每3周重复1次,共行2~4个周期。化疗结束后进行临床疗效及不良反应的评估。结果:30例局部进展期胃癌患者接受了EOF方案的化疗,完全缓解(complete response,CR)为3.3%(1/30),部分缓解(partial response,PR)为26.7%(8/30),疾病稳定(stable disease,SD)为46.7%(14/30),疾病进展(progressive disease,PD)为23.3%(7/30),临床总有效率(CR+PR)为30%(9/30)。66.7%(20/30)的患者行手术切除,其中46.7%(14/30)获得根治性切除,20%(6/30)行姑息性手术。主要的化疗不良反应为白细胞减少53.3%(16/30),中性粒细胞减少53.3%(16/30),食欲减退43.3%(13/30),无化疗相关死亡。结论:EOF方案在局部进展期胃癌的治疗中是安全有效且耐受良好的方案。

关键词: 局部晚期胃癌, 转化性化疗, 奥沙利铂, 表柔比星, 氟尿嘧啶

Abstract: Background and Purpose: This study aimed to evaluate the efficacy and toxicity of chemotherapy using the modified EOF (oxaliplatin, epirubicin, calcium folinate, 5-fluorouracil) regimen in patients with locally advanced gastric cancer. Methods: Thirty patients diagnosed with locally advanced gastric cancer were included into this clinical trial. All these patients received the chemotherapy of modified EOF regimen. This regimen consisted of oxaliplatin at 130 mg/m2 intravenously (2 h) on day 1, epirubicin at 50 mg/m2 intravenously (2 h) on day 1, 5-fluorouracil at 2 400 mg/m2 intravenously (48 h). All patients received two to four cycles of chemotherapy. After completing the two cycles of chemotherapy, the clinical efficacy and toxicity of chemotherapy would be evaluated. Results: Thirty patients completed the planned treatment. The clinical efficacy rate was 30.0% (9/30) with 3.3% (1/30) complete response (CR) and 26.7% (8/30) partial response (PR) according to the RECIST criteria. The rates of stable disease (SD) and progressive disease (PD) were 46.7% (14/30) and 23.3% (7/30), respectively. In the trial, 66.7% (20/30) patients underwent surgery, 46.7% (14/30) patients had curative gastrectomy, and 20.0% (6/30) patients received palliative gastrectomy. The most common toxicities were leukopenia 53.3% (16/30), neutropenia 53.3% (16/30), and anorexia 43.3% (13/30). Conclusion: The EOF regimen is one of the effective and well-tolerated conversional chemotherapy regimens in locally advanced gastric cancer.

Key words: Gastric cancer, Conversional chemotherapy, Oxaliplatin, Epirubicin, 5-fluorouracil